We are international
Donate
• advocacy   TEXT SIZE   
latest news and info    back

ASCO 2013: Dr. Ghobrial - Phase I study of TH-302, an investigational hypoxia-targeted drug, and dex in patients with RRMM

Irene M. Ghobrial, MD
Dana-Farber Cancer Institute
Boston, MA

06.11.13


To view the video full screen, click on the small button next to the volume control in the lower right hand corner.


 related articles